Oral Insulin Formulation Provides Multiday Blood Glucose Control in Initial Human Study

EGY-NANO PHARMA has successfully completed a study in humans that showed multiday control of blood glucose levels in Type I and Type II diabetics following oral administration of a proprietary controlled release, mucoadhesive insulin formulation. This press release was prepared by Pabst Patent Group on behalf of EGY-NANO PHARMA.

(PRWEB) June 21, 2017 -- A proprietary controlled release, mucoadhesive insulin formulation has been developed and tested. Initial studies showed efficacy in rabbits and goat models of diabetes.

The formulation was then tested in humans. A study of six human patients (one type I and five type II; male and female; age range 19-62 years of age; disease duration 4 months to 12 years) was conducted. Blood glucose levels were normalized for periods up to four days, following a single oral dosage. The response was dose dependent.

EGY-NANO PHARMA is an early stage drug delivery company. Its initial focus is on developing an oral insulin product that provides prolonged control of blood glucose in diabetic patients. The platform technology has applications for oral or vaginal administration of other pharmaceuticals.

The technology uses natural polymers and GRAS ingredients to provide for sustained, controlled release of entrapped pharmaceutical following oral ingestion or intravaginal administration.

Patent protection is pending.

The technology is available for licensing or partnering.

This press release has been prepared for distribution on behalf of EGY-NANO PHARMA by Pabst Patent Group LLP, 1545 Peachtree St NE Suite 320, Atlanta, GA 30309. Additional information on the insulin formulation or other applications of the platform for oral or vaginal delivery is available upon request and execution of confidential disclosure agreement.
Contact Information
Patrea L. Pabst
Pabst Patent Group LLP
+1 404-879-2151

Online Web 2.0 Version
You can read the online version of this press release here.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears here - PRWeb ebooks - Another online visibility tool from PRWeb